Cargando…
Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy
Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myel...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053367/ https://www.ncbi.nlm.nih.gov/pubmed/24918438 http://dx.doi.org/10.1371/journal.pone.0099026 |
_version_ | 1782320366778056704 |
---|---|
author | Takahashi, Kazuo Raska, Milan Stuchlova Horynova, Milada Hall, Stacy D. Poulsen, Knud Kilian, Mogens Hiki, Yoshiyuki Yuzawa, Yukio Moldoveanu, Zina Julian, Bruce A. Renfrow, Matthew B. Novak, Jan |
author_facet | Takahashi, Kazuo Raska, Milan Stuchlova Horynova, Milada Hall, Stacy D. Poulsen, Knud Kilian, Mogens Hiki, Yoshiyuki Yuzawa, Yukio Moldoveanu, Zina Julian, Bruce A. Renfrow, Matthew B. Novak, Jan |
author_sort | Takahashi, Kazuo |
collection | PubMed |
description | Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3-sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins. |
format | Online Article Text |
id | pubmed-4053367 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-40533672014-06-18 Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy Takahashi, Kazuo Raska, Milan Stuchlova Horynova, Milada Hall, Stacy D. Poulsen, Knud Kilian, Mogens Hiki, Yoshiyuki Yuzawa, Yukio Moldoveanu, Zina Julian, Bruce A. Renfrow, Matthew B. Novak, Jan PLoS One Research Article Patients with IgA nephropathy (IgAN) have elevated circulating levels of IgA1 with some O-glycans consisting of galactose (Gal)-deficient N-acetylgalactosamine (GalNAc) with or without N-acetylneuraminic acid (NeuAc). We have analyzed O-glycosylation heterogeneity of naturally asialo-IgA1 (Ale) myeloma protein that mimics Gal-deficient IgA1 (Gd-IgA1) of patients with IgAN, except that IgA1 O-glycans of IgAN patients are frequently sialylated. Specifically, serum IgA1 of healthy controls has more α2,3-sialylated O-glycans (NeuAc attached to Gal) than α2,6-sialylated O-glycans (NeuAc attached to GalNAc). As IgA1-producing cells from IgAN patients have an increased activity of α2,6-sialyltransferase (ST6GalNAc), we hypothesize that such activity may promote premature sialylation of GalNAc and, thus, production of Gd-IgA1, as sialylation of GalNAc prevents subsequent Gal attachment. Distribution of NeuAc in IgA1 O-glycans may play an important role in the pathogenesis of IgAN. To better understand biological functions of NeuAc in IgA1, we established protocols for enzymatic sialylation leading to α2,3- or α2,6-sialylation of IgA1 O-glycans. Sialylation of Gal-deficient asialo-IgA1 (Ale) myeloma protein by an ST6GalNAc enzyme generated sialylated IgA1 that mimics the Gal-deficient IgA1 glycoforms in patients with IgAN, characterized by α2,6-sialylated Gal-deficient GalNAc. In contrast, sialylation of the same myeloma protein by an α2,3-sialyltransferase yielded IgA1 typical for healthy controls, characterized by α2,3-sialylated Gal. The GalNAc-specific lectin from Helix aspersa (HAA) is used to measure levels of Gd-IgA1. We assessed HAA binding to IgA1 sialylated at Gal or GalNAc. As expected, α2,6-sialylation of IgA1 markedly decreased reactivity with HAA. Notably, α2,3-sialylation also decreased reactivity with HAA. Neuraminidase treatment recovered the original HAA reactivity in both instances. These results suggest that binding of a GalNAc-specific lectin is modulated by sialylation of GalNAc as well as Gal in the clustered IgA1 O-glycans. Thus, enzymatic sialylation offers a useful model to test the role of NeuAc in reactivities of the clustered O-glycans with lectins. Public Library of Science 2014-06-11 /pmc/articles/PMC4053367/ /pubmed/24918438 http://dx.doi.org/10.1371/journal.pone.0099026 Text en © 2014 Takahashi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Takahashi, Kazuo Raska, Milan Stuchlova Horynova, Milada Hall, Stacy D. Poulsen, Knud Kilian, Mogens Hiki, Yoshiyuki Yuzawa, Yukio Moldoveanu, Zina Julian, Bruce A. Renfrow, Matthew B. Novak, Jan Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy |
title | Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy |
title_full | Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy |
title_fullStr | Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy |
title_full_unstemmed | Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy |
title_short | Enzymatic Sialylation of IgA1 O-Glycans: Implications for Studies of IgA Nephropathy |
title_sort | enzymatic sialylation of iga1 o-glycans: implications for studies of iga nephropathy |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053367/ https://www.ncbi.nlm.nih.gov/pubmed/24918438 http://dx.doi.org/10.1371/journal.pone.0099026 |
work_keys_str_mv | AT takahashikazuo enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT raskamilan enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT stuchlovahorynovamilada enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT hallstacyd enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT poulsenknud enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT kilianmogens enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT hikiyoshiyuki enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT yuzawayukio enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT moldoveanuzina enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT julianbrucea enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT renfrowmatthewb enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy AT novakjan enzymaticsialylationofiga1oglycansimplicationsforstudiesofiganephropathy |